The CEO said the phase three OPERO1 monotherapy trial of palizestrant in the second, third-line setting reads out in Q1. Phase two data showed median PFS of 7.3 months in ESR1 mutant patients and 5.5 months in ESR1 wild-type patients. The trial assesses both ESR1 mutant and wild-type patients as individual endpoints.
OLMA · Olema Oncology, Inc. · Documents
Substantial doubt about the company's ability to continue as a going concern.
“As a result, these conditions raise substantial doubt about our ability to continue as a going concern over the long term.”View the 10-Q filed Nov 10, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
Olema Oncology, Inc. changed its name from Olema Pharmaceuticals, Inc. effective November 12, 2026. It also relocated its principal executive offices to 365 Oyster Point Blvd., Suite 400, South San Francisco, California 94080.
Olima Oncology expects an Opera 01 readout in Q1, said Opera 2 is enrolling “extremely robustly,” and reported $414 million cash, with a possible mid-year 2028 launch.
Olema expects Phase III topline results in Q1 of next year, including ESR-1 mutant and ESR-1 wild type subsets; cash on hand of about $414 million provides runway into 2028.
Olema reported a $189.9 million net loss for the nine months ended September 30, 2026. Palazestrant’s Phase 3 OPERA-01 top-line results are expected in the first quarter of 2027, followed by an NDA submission in 2027.
Olema Pharmaceuticals reported a $73.6 million net loss for the quarter ended September 30, 2026 and held $413.8 million in cash, cash equivalents, and marketable securities. It remains on track for OPERA-01 top-line data in the first quarter of 2027.
Dr. Gorjan Hrustanovic resigned from Olema Pharmaceuticals, Inc.’s Board of Directors and two committees effective October 14, 2026, without any disagreement over operations, policies or practices; Dr. Prakash Raman joined both committees effective October 15, 2026.